Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study

Table 4 Incidence of biomarkers in grade IV gliomas in other studies

Study	Year	Country	Number of patients tested	Incidence of Positive Biomarkers (%)
Study	Year	Country	Number of patients tested	MGMT promoter methylation	1p19q co-deletion	IDH1 mutation	ATRX loss
Tang et al. [17]	2011	China	79	33
Lechapt-Zalman et al. [26]	2012	France	110	57
Nehru et al. [22]	2012	India	27	63
Boots-Sprenger et al. [24]	2013	Netherlands	321 (MGMT)	27
			325 (1p19q)		3
			223 (IDH1)			16
McDonald et al. [25]	2015	Australia	33	48
Ogura et al. [20]	2015	Japan	165	46		4
Yang et al. [18]	2015	China	238 (MGMT)	40
Yang et al. [18]	2015	China	260 (IDH1/2)			21^a
Cai et al. [30]	2016	China	114			15	12
Chaurasia et al. [34]	2016	Korea	163			10	15
Ebrahimi et al. [31]	2016	Germany	243 (IDH1/2)			7^a
Ebrahimi et al. [31]	2016	Germany	242 (ATRX)				11
Kramář et al. [33]	2016	Czechoslovakia	58			17^a
Li et al. [19]	2016	China	145	30		17
Tini et al. [27]	2016	Italy	169	50

^aIncludes IDH2 mutations. MGMT O⁶-methylguanine-DNA-transferase; IDH1 isocitrate dehydrogenase 1; ATRX alpha-thalassemia/mental retardation syndrome X-linked

ISSN: 1471-2407